<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Publication:
Caffeine use in preterm neonates: national insights into Turkish NICU practices

Loading...
Thumbnail Image

Departments

Item type:Organizational Unit,
Item type:Organizational Unit,

School / College / Institute

Item type:Organizational Unit,
SCHOOL OF MEDICINE
Upper Org Unit
Item type:Organizational Unit,

Program

Organization Authors

Co-Authors

Unal, Sezin

Beken, Serdar

Ince, Deniz Anuk

Turan, Ozden

Toygar, Ayse Korkmaz

Ecevit, Ayse

Akcan, Abdullah Baris

Akin, Mustafa Ali

Aktas, Selma

Ciftdemir, Nukhet Aladag

Date

Language

Embargo Status

No

Journal Title

Journal ISSN

Volume Title

Alternative Title

Abstract

Objective: Caffeine is a proven medication used for the prevention and treatment of apnea in premature infants, offering both short- and long-term benefits. International guidelines provide a range of recommendations regarding the preterm population eligible for caffeine prophylaxis, including the timing, dosage, and duration of treatment. Our national guidelines, published prior to the most recent updates of the international guidelines, recommend the use of caffeine citrate starting from the first day after delivery for preterm infants with a gestational age of <28 weeks. For infants up to 32 weeks, if positive pressure ventilation is required, the decision should be made on an individual basis. This study aims to describe the variability in caffeine usage across neonatal intensive care units in our country. Methods: An online survey was sent to neonatologist who are members of the Turkish Neonatology Society to describe the variability in caffeine usage in neonatal intensive care units in our country. Results: We collected responses from 74 units. Prophylactic caffeine usage was observed as; GA <= 27(6/7): 98.6%, GA 28(0/7)-28(6/7): 89.0%, GA 29(0/7)-29(6/7): 75.3%, GA 30(0/7)-31(6/7): 53.4%. 62.2% of units reported administering loading dose within the first two hours. The initial maintenance dose was 5 mg/kg in 64.8% of units, 10 mg/kg in 32.4% of units, and intermediate dose in 5.3% of units. 47.3% of units reported no routine dose adjustment. The postmenstrual age that caffeine treatment was stopped was found to be 34 (min-max; 32-36) weeks for infants without apnea and respiratory support, 36 (min-max; 34-52) weeks for infants without apnea but any respiratory support. The time to discharge after treatment cessation was found as; 1-4 days: 37.8%, 5-7 days: 68.9%. Among the 56 units with multiple responsible physicians, 32.1% reported intra-unit variations. Conclusion: The significant differences in caffeine usage characteristics between and within units highlight the need for clear recommendations provided by standardized guidelines.

Source

Publisher

Frontiers

Citation

item.page.haspartof

Source

Frontiers in Pediatrics

item.page.ispartofseries

item.page.edition

DOI

10.3389/fped.2025.1492716

item.page.datauri

item.page.link

Rights

CC BY (Attribution)

Copyrights Note

Creative Commons license

Except where otherwise noted, this item's license is described as CC BY (Attribution)

Endorsement

Review

Supplemented By

Referenced By

Related Patent

Related Goal

Google Scholar
Scholar'da Ara ↗
0
Görüntülenme
1
İndirme
Altmetric
Dimensions
PlumX Metrikleri
BIP! Indicators